Additionally, a phase 1b trial evaluated the use of sintilimab and anlotinib in the frontline treatment of advanced NSCLC regardless of the PD-L1 expression level or TMB; this chemotherapy-free regimen exhibited encouraging efficacy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.